Midostaurin in FLT3-Mutated Acute Myeloid Leukemia.
作者信息
Sahoo Ranjit K, Kumar Lalit
机构信息
All India Institute of Medical Sciences, New Delhi, India
出版信息
N Engl J Med. 2017 Nov 9;377(19):1901-2. doi: 10.1056/NEJMc1711340.
PMID:29120133
Abstract
摘要
相似文献
1
Midostaurin in FLT3-Mutated Acute Myeloid Leukemia.米哚妥林治疗FLT3突变的急性髓系白血病
N Engl J Med. 2017 Nov 9;377(19):1901-2. doi: 10.1056/NEJMc1711340.
2
Midostaurin treatment in FLT3-mutated acute myeloid leukemia and systemic mastocytosis.米哚妥林治疗FLT3突变的急性髓系白血病和系统性肥大细胞增多症。
Expert Rev Clin Pharmacol. 2017 Nov;10(11):1177-1189. doi: 10.1080/17512433.2017.1387051. Epub 2017 Oct 10.
3
[Research Progress on Treating Acute Myeloid Leukemia by Midostaurin].
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2015 Dec;23(6):1780-4. doi: 10.7534/j.issn.1009-2137.2015.06.045.
4
Midostaurin/PKC412 for the treatment of newly diagnosed FLT3 mutation-positive acute myeloid leukemia.米哚妥林/PKC412用于治疗新诊断的FLT3突变阳性急性髓系白血病。
Expert Rev Hematol. 2017 Dec;10(12):1033-1045. doi: 10.1080/17474086.2017.1397510. Epub 2017 Oct 30.
5
Midostaurin in FLT3-Mutated Acute Myeloid Leukemia.米哚妥林用于FLT3突变的急性髓系白血病
N Engl J Med. 2017 Nov 9;377(19):1903. doi: 10.1056/NEJMc1711340.
6
Midostaurin in FLT3-Mutated Acute Myeloid Leukemia.
N Engl J Med. 2017 Nov 9;377(19):1901. doi: 10.1056/NEJMc1711340.
7
Midostaurin: A New Oral Agent Targeting FMS-Like Tyrosine Kinase 3-Mutant Acute Myeloid Leukemia.米哚妥林：一种新型靶向 FMS 样酪氨酸激酶 3 突变的口服药物治疗急性髓系白血病。
Pharmacotherapy. 2017 Dec;37(12):1586-1599. doi: 10.1002/phar.2039. Epub 2017 Nov 23.
8
Midostaurin for the treatment of adult patients with newly diagnosed acute myeloid leukemia that is FLT3 mutation-positive.米哚妥林用于治疗新诊断的FLT3突变阳性的成年急性髓系白血病患者。
Drugs Today (Barc). 2017 Oct;53(10):531-543. doi: 10.1358/dot.2017.53.10.2717625.
9
Midostaurin in FLT3-mutated acute myeloid leukaemia.米哚妥林治疗FLT3突变的急性髓系白血病
Lancet Oncol. 2017 Aug;18(8):e439. doi: 10.1016/S1470-2045(17)30506-5. Epub 2017 Jun 29.
10
Midostaurin for the treatment of acute myeloid leukemia.米哚妥林治疗急性髓系白血病。
Future Oncol. 2017 Sep;13(21):1853-1871. doi: 10.2217/fon-2017-0160. Epub 2017 Jun 14.
引用本文的文献
1
LT-171-861, a novel FLT3 inhibitor, shows excellent preclinical efficacy for the treatment of FLT3 mutant acute myeloid leukemia.LT-171-861，一种新型的 FLT3 抑制剂，在治疗 FLT3 突变型急性髓系白血病方面显示出优异的临床前疗效。
Theranostics. 2021 Jan 1;11(1):93-106. doi: 10.7150/thno.46593. eCollection 2021.
Zotero 插件